{"id":"W2922787184","doi":"10.1016/j.kint.2019.02.033","title":"Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","year":2019,"lang":"en","type":"article","venue":"Kidney International","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; University of Toronto; University Health Network; Juvenile Diabetes Research Foundation Canada; AstraZeneca; Canadian Diabetes Association; Novo Nordisk; AbbVie; Boehringer Ingelheim; Eli Lilly and Company","keywords":"Empagliflozin; Medicine; EMPA; Internal medicine; Kidney disease; Diabetes mellitus; Placebo; Diabetic nephropathy; Nephropathy; Type 2 diabetes; Cardiology; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003182789,0.000781107,0.001959745,0.0002592282,0.000216297,0.001186651,0.0004420168,0.0007369045,0.005087982],"category_scores_gemma":[0.004056741,0.0002531042,0.004543711,0.0004583347,0.000343782,0.0008766033,0.0005223154,0.002413673,0.0005908168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002985516,"about_ca_system_score_gemma":0.0005662023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001228681,"about_ca_topic_score_gemma":0.002688957,"domain_scores_codex":[0.9987992,0.0006434621,0.0001008826,0.0001838527,0.0001584922,0.0001141044],"domain_scores_gemma":[0.9979177,0.0010186,0.0004716633,0.0002428528,0.0001481775,0.0002009917],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7066748,0.001432059,0.05974615,0.004515725,0.03616355,0.0002402576,0.00006792609,0.002159217,0.003359159,0.001317434,0.02651518,0.1578085],"study_design_scores_gemma":[0.3616899,0.03392193,0.4454829,0.00115477,0.1151332,0.0004709655,0.0001225241,0.005052508,0.002542873,0.005455138,0.02880806,0.0001653712],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8727134,0.06423954,0.005362446,0.01155315,0.001999831,0.0009021485,0.0201811,0.0005425023,0.02250584],"genre_scores_gemma":[0.9668958,0.01031877,0.001936209,0.005578475,0.001438172,0.0003885931,0.009254068,0.00006108605,0.004128784],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005087982,"threshold_uncertainty_score":0.01702094,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008964440251845096,"score_gpt":0.2819541485866346,"score_spread":0.2729897083347895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}